Read more about the article Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang,…

Continue ReadingCongrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!
Read more about the article Please join us for an update on our AlloCAR T platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR T platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue ReadingPlease join us for an update on our AlloCAR T platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO
Read more about the article Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue ReadingToday we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue ReadingThis month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.
Read more about the article ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy
Read more about the article Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Read more about the article Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
Read more about the article Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy